nodes	percent_of_prediction	percent_of_DWPC	metapath
Indomethacin—GLO1—esophageal cancer	0.299	0.662	CbGaD
Indomethacin—CES1—Capecitabine—esophageal cancer	0.0749	0.201	CbGbCtD
Indomethacin—ABCC2—esophageal cancer	0.0599	0.132	CbGaD
Indomethacin—ABCC11—Methotrexate—esophageal cancer	0.059	0.159	CbGbCtD
Indomethacin—ABCC6—Cisplatin—esophageal cancer	0.0522	0.14	CbGbCtD
Indomethacin—PTGS1—esophageal cancer	0.0453	0.1	CbGaD
Indomethacin—PTGS2—esophageal cancer	0.0259	0.0573	CbGaD
Indomethacin—ABCC3—Cisplatin—esophageal cancer	0.0251	0.0674	CbGbCtD
Indomethacin—ABCB1—esophageal cancer	0.022	0.0487	CbGaD
Indomethacin—ABCC3—Methotrexate—esophageal cancer	0.0163	0.0437	CbGbCtD
Indomethacin—SLC22A11—Methotrexate—esophageal cancer	0.0134	0.0359	CbGbCtD
Indomethacin—ABCC2—Carboplatin—esophageal cancer	0.0133	0.0358	CbGbCtD
Indomethacin—SLC22A7—Methotrexate—esophageal cancer	0.0127	0.0342	CbGbCtD
Indomethacin—ABCC4—Methotrexate—esophageal cancer	0.0124	0.0334	CbGbCtD
Indomethacin—ABCC2—Cisplatin—esophageal cancer	0.0114	0.0306	CbGbCtD
Indomethacin—PTGS2—Cisplatin—esophageal cancer	0.0113	0.0303	CbGbCtD
Indomethacin—ABCC1—Methotrexate—esophageal cancer	0.01	0.0269	CbGbCtD
Indomethacin—SLCO1A2—Methotrexate—esophageal cancer	0.00893	0.024	CbGbCtD
Indomethacin—SLCO1B1—Methotrexate—esophageal cancer	0.00842	0.0226	CbGbCtD
Indomethacin—SLC22A8—Methotrexate—esophageal cancer	0.00777	0.0209	CbGbCtD
Indomethacin—CYP2C9—Capecitabine—esophageal cancer	0.0076	0.0204	CbGbCtD
Indomethacin—ABCC2—Methotrexate—esophageal cancer	0.0074	0.0199	CbGbCtD
Indomethacin—Secondary anemia—Cisplatin—esophageal cancer	0.00694	0.134	CcSEcCtD
Indomethacin—SLC22A6—Methotrexate—esophageal cancer	0.00541	0.0145	CbGbCtD
Indomethacin—ALB—Methotrexate—esophageal cancer	0.00461	0.0124	CbGbCtD
Indomethacin—CYP2C9—Cisplatin—esophageal cancer	0.00383	0.0103	CbGbCtD
Indomethacin—ABCB1—Cisplatin—esophageal cancer	0.00372	0.00998	CbGbCtD
Indomethacin—CES1—larynx—esophageal cancer	0.00293	0.0799	CbGeAlD
Indomethacin—Necrotizing enterocolitis—Capecitabine—esophageal cancer	0.0026	0.0502	CcSEcCtD
Indomethacin—Necrotising enterocolitis neonatal—Capecitabine—esophageal cancer	0.0026	0.0502	CcSEcCtD
Indomethacin—ABCB1—Methotrexate—esophageal cancer	0.00241	0.00648	CbGbCtD
Indomethacin—Necrotising colitis—Capecitabine—esophageal cancer	0.00213	0.041	CcSEcCtD
Indomethacin—Abdominal distress—Methotrexate—esophageal cancer	0.00135	0.026	CcSEcCtD
Indomethacin—Lung infection—Methotrexate—esophageal cancer	0.00111	0.0215	CcSEcCtD
Indomethacin—PPARA—neck—esophageal cancer	0.00105	0.0286	CbGeAlD
Indomethacin—PTGR2—lung—esophageal cancer	0.000844	0.023	CbGeAlD
Indomethacin—GLO1—epithelium—esophageal cancer	0.00082	0.0224	CbGeAlD
Indomethacin—GLO1—bronchus—esophageal cancer	0.000808	0.022	CbGeAlD
Indomethacin—Necrolysis epidermal—Methotrexate—esophageal cancer	0.000803	0.0155	CcSEcCtD
Indomethacin—GLO1—smooth muscle tissue—esophageal cancer	0.00079	0.0216	CbGeAlD
Indomethacin—CES1—neck—esophageal cancer	0.000777	0.0212	CbGeAlD
Indomethacin—PLA2G2A—epithelium—esophageal cancer	0.000763	0.0208	CbGeAlD
Indomethacin—PLA2G2A—bronchus—esophageal cancer	0.000751	0.0205	CbGeAlD
Indomethacin—CXCL8—bronchus—esophageal cancer	0.000743	0.0203	CbGeAlD
Indomethacin—PLA2G2A—smooth muscle tissue—esophageal cancer	0.000735	0.02	CbGeAlD
Indomethacin—CXCL8—smooth muscle tissue—esophageal cancer	0.000727	0.0198	CbGeAlD
Indomethacin—GLO1—trachea—esophageal cancer	0.000725	0.0198	CbGeAlD
Indomethacin—PPARA—epithelium—esophageal cancer	0.000712	0.0194	CbGeAlD
Indomethacin—PPARA—smooth muscle tissue—esophageal cancer	0.000686	0.0187	CbGeAlD
Indomethacin—Leukaemia—Methotrexate—esophageal cancer	0.000677	0.0131	CcSEcCtD
Indomethacin—PLA2G2A—trachea—esophageal cancer	0.000674	0.0184	CbGeAlD
Indomethacin—CXCL8—trachea—esophageal cancer	0.000667	0.0182	CbGeAlD
Indomethacin—GLO1—digestive system—esophageal cancer	0.000624	0.017	CbGeAlD
Indomethacin—UGT1A9—digestive system—esophageal cancer	0.000606	0.0165	CbGeAlD
Indomethacin—AKR1C3—bronchus—esophageal cancer	0.000583	0.0159	CbGeAlD
Indomethacin—PLA2G2A—digestive system—esophageal cancer	0.00058	0.0158	CbGeAlD
Indomethacin—PTGR2—lymph node—esophageal cancer	0.000577	0.0157	CbGeAlD
Indomethacin—PPARG—neck—esophageal cancer	0.000576	0.0157	CbGeAlD
Indomethacin—AKR1C3—smooth muscle tissue—esophageal cancer	0.00057	0.0156	CbGeAlD
Indomethacin—Bromfenac—PTGS1—esophageal cancer	0.000552	0.292	CrCbGaD
Indomethacin—PPARA—digestive system—esophageal cancer	0.000542	0.0148	CbGeAlD
Indomethacin—AKR1C3—trachea—esophageal cancer	0.000523	0.0143	CbGeAlD
Indomethacin—Proctalgia—Capecitabine—esophageal cancer	0.000522	0.0101	CcSEcCtD
Indomethacin—GLO1—lung—esophageal cancer	0.000521	0.0142	CbGeAlD
Indomethacin—SLC10A1—digestive system—esophageal cancer	0.000521	0.0142	CbGeAlD
Indomethacin—Pneumothorax—Capecitabine—esophageal cancer	0.000492	0.00951	CcSEcCtD
Indomethacin—UGT2B7—digestive system—esophageal cancer	0.000488	0.0133	CbGeAlD
Indomethacin—PLA2G2A—lung—esophageal cancer	0.000484	0.0132	CbGeAlD
Indomethacin—CXCL8—lung—esophageal cancer	0.00048	0.0131	CbGeAlD
Indomethacin—ABCC6—lung—esophageal cancer	0.00048	0.0131	CbGeAlD
Indomethacin—SLC22A11—digestive system—esophageal cancer	0.000476	0.013	CbGeAlD
Indomethacin—SLC22A7—digestive system—esophageal cancer	0.000464	0.0127	CbGeAlD
Indomethacin—PPARA—lung—esophageal cancer	0.000453	0.0123	CbGeAlD
Indomethacin—UGT1A1—digestive system—esophageal cancer	0.000415	0.0113	CbGeAlD
Indomethacin—Platelet count decreased—Capecitabine—esophageal cancer	0.000412	0.00795	CcSEcCtD
Indomethacin—CES1—digestive system—esophageal cancer	0.000402	0.011	CbGeAlD
Indomethacin—Ulcerative stomatitis—Methotrexate—esophageal cancer	0.000395	0.00763	CcSEcCtD
Indomethacin—PPARG—epithelium—esophageal cancer	0.000392	0.0107	CbGeAlD
Indomethacin—Respiratory distress—Capecitabine—esophageal cancer	0.000386	0.00745	CcSEcCtD
Indomethacin—Tenderness—Cisplatin—esophageal cancer	0.000381	0.00735	CcSEcCtD
Indomethacin—PPARG—smooth muscle tissue—esophageal cancer	0.000377	0.0103	CbGeAlD
Indomethacin—AKR1C3—lung—esophageal cancer	0.000376	0.0103	CbGeAlD
Indomethacin—Tolmetin—PTGS1—esophageal cancer	0.000371	0.196	CrCbGaD
Indomethacin—Bone marrow depression—Capecitabine—esophageal cancer	0.000363	0.00701	CcSEcCtD
Indomethacin—GLO1—lymph node—esophageal cancer	0.000356	0.00972	CbGeAlD
Indomethacin—Ulcer—Cisplatin—esophageal cancer	0.000351	0.00678	CcSEcCtD
Indomethacin—Dysarthria—Cisplatin—esophageal cancer	0.000351	0.00678	CcSEcCtD
Indomethacin—ABCC4—bronchus—esophageal cancer	0.00035	0.00955	CbGeAlD
Indomethacin—Ileus—Capecitabine—esophageal cancer	0.000346	0.00668	CcSEcCtD
Indomethacin—Pain—Carboplatin—esophageal cancer	0.000346	0.00667	CcSEcCtD
Indomethacin—SLCO1B1—digestive system—esophageal cancer	0.000345	0.00942	CbGeAlD
Indomethacin—Azotaemia—Methotrexate—esophageal cancer	0.000342	0.00661	CcSEcCtD
Indomethacin—CES1—lung—esophageal cancer	0.000336	0.00916	CbGeAlD
Indomethacin—PLA2G2A—lymph node—esophageal cancer	0.000331	0.00904	CbGeAlD
Indomethacin—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.000331	0.00639	CcSEcCtD
Indomethacin—CXCL8—lymph node—esophageal cancer	0.000328	0.00895	CbGeAlD
Indomethacin—ABCC3—digestive system—esophageal cancer	0.000328	0.00894	CbGeAlD
Indomethacin—Hyperkalaemia—Cisplatin—esophageal cancer	0.000327	0.0063	CcSEcCtD
Indomethacin—Body temperature increased—Carboplatin—esophageal cancer	0.00032	0.00617	CcSEcCtD
Indomethacin—Skin exfoliation—Cisplatin—esophageal cancer	0.000317	0.00613	CcSEcCtD
Indomethacin—Fluid retention—Cisplatin—esophageal cancer	0.000316	0.00609	CcSEcCtD
Indomethacin—Bromfenac—PTGS2—esophageal cancer	0.000315	0.167	CrCbGaD
Indomethacin—Coagulopathy—Capecitabine—esophageal cancer	0.000315	0.00608	CcSEcCtD
Indomethacin—PPARA—lymph node—esophageal cancer	0.00031	0.00844	CbGeAlD
Indomethacin—ABCC1—bronchus—esophageal cancer	0.000299	0.00815	CbGeAlD
Indomethacin—PPARG—digestive system—esophageal cancer	0.000298	0.00813	CbGeAlD
Indomethacin—Petechiae—Capecitabine—esophageal cancer	0.000298	0.00575	CcSEcCtD
Indomethacin—SLCO1A2—digestive system—esophageal cancer	0.000281	0.00767	CbGeAlD
Indomethacin—Naproxen—PTGS1—esophageal cancer	0.000279	0.148	CrCbGaD
Indomethacin—Proteinuria—Capecitabine—esophageal cancer	0.000279	0.00538	CcSEcCtD
Indomethacin—Protein urine present—Capecitabine—esophageal cancer	0.000275	0.00531	CcSEcCtD
Indomethacin—ABCC3—lung—esophageal cancer	0.000274	0.00747	CbGeAlD
Indomethacin—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000271	0.00524	CcSEcCtD
Indomethacin—ABCC4—digestive system—esophageal cancer	0.000271	0.00738	CbGeAlD
Indomethacin—Bone marrow depression—Methotrexate—esophageal cancer	0.00027	0.00522	CcSEcCtD
Indomethacin—Deafness—Cisplatin—esophageal cancer	0.00027	0.00521	CcSEcCtD
Indomethacin—ABCC1—trachea—esophageal cancer	0.000268	0.00731	CbGeAlD
Indomethacin—Haemolytic anaemia—Cisplatin—esophageal cancer	0.000267	0.00516	CcSEcCtD
Indomethacin—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000266	0.00514	CcSEcCtD
Indomethacin—ABCC2—digestive system—esophageal cancer	0.000262	0.00714	CbGeAlD
Indomethacin—Dysarthria—Capecitabine—esophageal cancer	0.000259	0.005	CcSEcCtD
Indomethacin—Ulcer—Capecitabine—esophageal cancer	0.000259	0.005	CcSEcCtD
Indomethacin—AKR1C3—lymph node—esophageal cancer	0.000257	0.00701	CbGeAlD
Indomethacin—PPARG—lung—esophageal cancer	0.000249	0.00679	CbGeAlD
Indomethacin—Hyponatraemia—Cisplatin—esophageal cancer	0.000242	0.00468	CcSEcCtD
Indomethacin—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000241	0.00466	CcSEcCtD
Indomethacin—Colitis—Capecitabine—esophageal cancer	0.000235	0.00454	CcSEcCtD
Indomethacin—SLCO1A2—lung—esophageal cancer	0.000235	0.0064	CbGeAlD
Indomethacin—Skin exfoliation—Capecitabine—esophageal cancer	0.000234	0.00452	CcSEcCtD
Indomethacin—Fluid retention—Capecitabine—esophageal cancer	0.000233	0.00449	CcSEcCtD
Indomethacin—CES1—lymph node—esophageal cancer	0.00023	0.00626	CbGeAlD
Indomethacin—ABCC4—lung—esophageal cancer	0.000226	0.00616	CbGeAlD
Indomethacin—CYP2C19—digestive system—esophageal cancer	0.000225	0.00614	CbGeAlD
Indomethacin—Petechiae—Methotrexate—esophageal cancer	0.000222	0.00428	CcSEcCtD
Indomethacin—Mouth ulceration—Capecitabine—esophageal cancer	0.000221	0.00428	CcSEcCtD
Indomethacin—Ecchymosis—Capecitabine—esophageal cancer	0.000221	0.00428	CcSEcCtD
Indomethacin—Apnoea—Methotrexate—esophageal cancer	0.000215	0.00415	CcSEcCtD
Indomethacin—Tolmetin—PTGS2—esophageal cancer	0.000212	0.112	CrCbGaD
Indomethacin—PTGS1—epithelium—esophageal cancer	0.000209	0.00571	CbGeAlD
Indomethacin—Proteinuria—Methotrexate—esophageal cancer	0.000208	0.00401	CcSEcCtD
Indomethacin—Thrombophlebitis—Capecitabine—esophageal cancer	0.000205	0.00397	CcSEcCtD
Indomethacin—Protein urine present—Methotrexate—esophageal cancer	0.000205	0.00395	CcSEcCtD
Indomethacin—PTGS1—smooth muscle tissue—esophageal cancer	0.000202	0.0055	CbGeAlD
Indomethacin—Gastroenteritis—Capecitabine—esophageal cancer	0.000201	0.00387	CcSEcCtD
Indomethacin—PTGS2—epithelium—esophageal cancer	0.0002	0.00546	CbGeAlD
Indomethacin—Abdominal discomfort—Cisplatin—esophageal cancer	0.0002	0.00386	CcSEcCtD
Indomethacin—Deafness—Capecitabine—esophageal cancer	0.000199	0.00384	CcSEcCtD
Indomethacin—Vascular purpura—Capecitabine—esophageal cancer	0.000199	0.00384	CcSEcCtD
Indomethacin—Pancytopenia—Cisplatin—esophageal cancer	0.000198	0.00382	CcSEcCtD
Indomethacin—Oliguria—Methotrexate—esophageal cancer	0.000198	0.00382	CcSEcCtD
Indomethacin—PTGS2—bronchus—esophageal cancer	0.000197	0.00538	CbGeAlD
Indomethacin—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000197	0.0038	CcSEcCtD
Indomethacin—Eye pain—Capecitabine—esophageal cancer	0.000197	0.0038	CcSEcCtD
Indomethacin—PTGS2—smooth muscle tissue—esophageal cancer	0.000193	0.00526	CbGeAlD
Indomethacin—Ulcer—Methotrexate—esophageal cancer	0.000193	0.00372	CcSEcCtD
Indomethacin—Dysarthria—Methotrexate—esophageal cancer	0.000193	0.00372	CcSEcCtD
Indomethacin—ABCC1—lung—esophageal cancer	0.000193	0.00526	CbGeAlD
Indomethacin—Hot flush—Capecitabine—esophageal cancer	0.00019	0.00367	CcSEcCtD
Indomethacin—Menopausal symptoms—Capecitabine—esophageal cancer	0.000188	0.00364	CcSEcCtD
Indomethacin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000188	0.00364	CcSEcCtD
Indomethacin—ABCC3—lymph node—esophageal cancer	0.000187	0.00511	CbGeAlD
Indomethacin—Renal impairment—Capecitabine—esophageal cancer	0.000187	0.00361	CcSEcCtD
Indomethacin—Vasculitis—Methotrexate—esophageal cancer	0.000187	0.00361	CcSEcCtD
Indomethacin—PTGS1—trachea—esophageal cancer	0.000185	0.00505	CbGeAlD
Indomethacin—Purpura—Capecitabine—esophageal cancer	0.000185	0.00356	CcSEcCtD
Indomethacin—Renal failure—Cisplatin—esophageal cancer	0.000183	0.00353	CcSEcCtD
Indomethacin—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000182	0.00352	CcSEcCtD
Indomethacin—Stomatitis—Cisplatin—esophageal cancer	0.000181	0.0035	CcSEcCtD
Indomethacin—Hyponatraemia—Capecitabine—esophageal cancer	0.000179	0.00345	CcSEcCtD
Indomethacin—Diplopia—Capecitabine—esophageal cancer	0.000178	0.00343	CcSEcCtD
Indomethacin—Osteoarthritis—Capecitabine—esophageal cancer	0.000178	0.00343	CcSEcCtD
Indomethacin—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000178	0.00343	CcSEcCtD
Indomethacin—PTGS2—trachea—esophageal cancer	0.000177	0.00483	CbGeAlD
Indomethacin—CYP2C9—digestive system—esophageal cancer	0.000174	0.00476	CbGeAlD
Indomethacin—Skin exfoliation—Methotrexate—esophageal cancer	0.000174	0.00336	CcSEcCtD
Indomethacin—Aplastic anaemia—Methotrexate—esophageal cancer	0.000171	0.00331	CcSEcCtD
Indomethacin—PPARG—lymph node—esophageal cancer	0.00017	0.00464	CbGeAlD
Indomethacin—Bradycardia—Cisplatin—esophageal cancer	0.00017	0.00328	CcSEcCtD
Indomethacin—Coma—Methotrexate—esophageal cancer	0.000167	0.00322	CcSEcCtD
Indomethacin—Mouth ulceration—Methotrexate—esophageal cancer	0.000165	0.00318	CcSEcCtD
Indomethacin—Ecchymosis—Methotrexate—esophageal cancer	0.000165	0.00318	CcSEcCtD
Indomethacin—Gynaecomastia—Methotrexate—esophageal cancer	0.000163	0.00315	CcSEcCtD
Indomethacin—Abdominal pain upper—Capecitabine—esophageal cancer	0.000162	0.00314	CcSEcCtD
Indomethacin—Pulmonary oedema—Methotrexate—esophageal cancer	0.000162	0.00313	CcSEcCtD
Indomethacin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00016	0.00309	CcSEcCtD
Indomethacin—ALB—lymph node—esophageal cancer	0.00016	0.00435	CbGeAlD
Indomethacin—Naproxen—PTGS2—esophageal cancer	0.000159	0.0845	CrCbGaD
Indomethacin—PTGS1—digestive system—esophageal cancer	0.000159	0.00434	CbGeAlD
Indomethacin—Gastritis—Capecitabine—esophageal cancer	0.000157	0.00304	CcSEcCtD
Indomethacin—Muscular weakness—Capecitabine—esophageal cancer	0.000157	0.00303	CcSEcCtD
Indomethacin—Tinnitus—Cisplatin—esophageal cancer	0.000156	0.003	CcSEcCtD
Indomethacin—Flushing—Cisplatin—esophageal cancer	0.000155	0.00299	CcSEcCtD
Indomethacin—Abdominal distension—Capecitabine—esophageal cancer	0.000155	0.00299	CcSEcCtD
Indomethacin—ABCC4—lymph node—esophageal cancer	0.000155	0.00422	CbGeAlD
Indomethacin—Asthma—Capecitabine—esophageal cancer	0.000154	0.00297	CcSEcCtD
Indomethacin—Thrombophlebitis—Methotrexate—esophageal cancer	0.000153	0.00295	CcSEcCtD
Indomethacin—PTGS2—digestive system—esophageal cancer	0.000152	0.00415	CbGeAlD
Indomethacin—ABCC2—lymph node—esophageal cancer	0.00015	0.00408	CbGeAlD
Indomethacin—Arrhythmia—Cisplatin—esophageal cancer	0.000149	0.00288	CcSEcCtD
Indomethacin—Alopecia—Cisplatin—esophageal cancer	0.000147	0.00285	CcSEcCtD
Indomethacin—Abdominal discomfort—Capecitabine—esophageal cancer	0.000147	0.00284	CcSEcCtD
Indomethacin—Pancytopenia—Capecitabine—esophageal cancer	0.000146	0.00282	CcSEcCtD
Indomethacin—Erythema—Cisplatin—esophageal cancer	0.000145	0.0028	CcSEcCtD
Indomethacin—Flatulence—Cisplatin—esophageal cancer	0.000143	0.00276	CcSEcCtD
Indomethacin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00014	0.00271	CcSEcCtD
Indomethacin—Weight increased—Capecitabine—esophageal cancer	0.00014	0.0027	CcSEcCtD
Indomethacin—Hyperglycaemia—Capecitabine—esophageal cancer	0.000139	0.00268	CcSEcCtD
Indomethacin—Vision blurred—Cisplatin—esophageal cancer	0.000137	0.00264	CcSEcCtD
Indomethacin—Depression—Capecitabine—esophageal cancer	0.000137	0.00264	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000136	0.00262	CcSEcCtD
Indomethacin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000135	0.0026	CcSEcCtD
Indomethacin—Renal failure—Capecitabine—esophageal cancer	0.000135	0.0026	CcSEcCtD
Indomethacin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000134	0.00259	CcSEcCtD
Indomethacin—Anaemia—Cisplatin—esophageal cancer	0.000134	0.00259	CcSEcCtD
Indomethacin—Jaundice—Capecitabine—esophageal cancer	0.000134	0.00258	CcSEcCtD
Indomethacin—Stomatitis—Capecitabine—esophageal cancer	0.000134	0.00258	CcSEcCtD
Indomethacin—PTGS1—lung—esophageal cancer	0.000133	0.00363	CbGeAlD
Indomethacin—Osteoarthritis—Methotrexate—esophageal cancer	0.000132	0.00256	CcSEcCtD
Indomethacin—ABCC1—lymph node—esophageal cancer	0.000132	0.00359	CbGeAlD
Indomethacin—Malaise—Cisplatin—esophageal cancer	0.000131	0.00253	CcSEcCtD
Indomethacin—Haematuria—Capecitabine—esophageal cancer	0.000131	0.00252	CcSEcCtD
Indomethacin—Leukopenia—Cisplatin—esophageal cancer	0.00013	0.00251	CcSEcCtD
Indomethacin—Epistaxis—Capecitabine—esophageal cancer	0.000129	0.0025	CcSEcCtD
Indomethacin—Agranulocytosis—Capecitabine—esophageal cancer	0.000128	0.00247	CcSEcCtD
Indomethacin—PTGS2—lung—esophageal cancer	0.000127	0.00347	CbGeAlD
Indomethacin—Convulsion—Cisplatin—esophageal cancer	0.000126	0.00243	CcSEcCtD
Indomethacin—Bradycardia—Capecitabine—esophageal cancer	0.000125	0.00242	CcSEcCtD
Indomethacin—ABCB1—epithelium—esophageal cancer	0.000124	0.00338	CbGeAlD
Indomethacin—Haemoglobin—Capecitabine—esophageal cancer	0.000124	0.00239	CcSEcCtD
Indomethacin—Anxiety—Cisplatin—esophageal cancer	0.000123	0.00238	CcSEcCtD
Indomethacin—Haemorrhage—Capecitabine—esophageal cancer	0.000123	0.00238	CcSEcCtD
Indomethacin—Hepatitis—Capecitabine—esophageal cancer	0.000123	0.00238	CcSEcCtD
Indomethacin—Discomfort—Cisplatin—esophageal cancer	0.000122	0.00236	CcSEcCtD
Indomethacin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000119	0.0023	CcSEcCtD
Indomethacin—Oedema—Cisplatin—esophageal cancer	0.000119	0.00229	CcSEcCtD
Indomethacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000119	0.00229	CcSEcCtD
Indomethacin—Erythema multiforme—Capecitabine—esophageal cancer	0.000116	0.00225	CcSEcCtD
Indomethacin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000116	0.00224	CcSEcCtD
Indomethacin—Tachycardia—Cisplatin—esophageal cancer	0.000116	0.00223	CcSEcCtD
Indomethacin—Tinnitus—Capecitabine—esophageal cancer	0.000115	0.00221	CcSEcCtD
Indomethacin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000115	0.00221	CcSEcCtD
Indomethacin—Asthma—Methotrexate—esophageal cancer	0.000114	0.00221	CcSEcCtD
Indomethacin—Flushing—Capecitabine—esophageal cancer	0.000114	0.0022	CcSEcCtD
Indomethacin—Anorexia—Cisplatin—esophageal cancer	0.000113	0.00218	CcSEcCtD
Indomethacin—Hypotension—Cisplatin—esophageal cancer	0.000111	0.00214	CcSEcCtD
Indomethacin—Arrhythmia—Capecitabine—esophageal cancer	0.00011	0.00212	CcSEcCtD
Indomethacin—Abdominal discomfort—Methotrexate—esophageal cancer	0.00011	0.00212	CcSEcCtD
Indomethacin—ABCB1—trachea—esophageal cancer	0.000109	0.00299	CbGeAlD
Indomethacin—Alopecia—Capecitabine—esophageal cancer	0.000109	0.0021	CcSEcCtD
Indomethacin—Pancytopenia—Methotrexate—esophageal cancer	0.000109	0.0021	CcSEcCtD
Indomethacin—Erythema—Capecitabine—esophageal cancer	0.000107	0.00207	CcSEcCtD
Indomethacin—Paraesthesia—Cisplatin—esophageal cancer	0.000106	0.00206	CcSEcCtD
Indomethacin—Dyspnoea—Cisplatin—esophageal cancer	0.000106	0.00204	CcSEcCtD
Indomethacin—Flatulence—Capecitabine—esophageal cancer	0.000106	0.00204	CcSEcCtD
Indomethacin—Decreased appetite—Cisplatin—esophageal cancer	0.000103	0.00199	CcSEcCtD
Indomethacin—Drowsiness—Methotrexate—esophageal cancer	0.000102	0.00197	CcSEcCtD
Indomethacin—Depression—Methotrexate—esophageal cancer	0.000102	0.00196	CcSEcCtD
Indomethacin—Pain—Cisplatin—esophageal cancer	0.000101	0.00196	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000101	0.00195	CcSEcCtD
Indomethacin—Vision blurred—Capecitabine—esophageal cancer	0.000101	0.00195	CcSEcCtD
Indomethacin—Renal failure—Methotrexate—esophageal cancer	0.0001	0.00194	CcSEcCtD
Indomethacin—Stomatitis—Methotrexate—esophageal cancer	9.94e-05	0.00192	CcSEcCtD
Indomethacin—Ill-defined disorder—Capecitabine—esophageal cancer	9.94e-05	0.00192	CcSEcCtD
Indomethacin—Anaemia—Capecitabine—esophageal cancer	9.9e-05	0.00191	CcSEcCtD
Indomethacin—Sweating—Methotrexate—esophageal cancer	9.78e-05	0.00189	CcSEcCtD
Indomethacin—Feeling abnormal—Cisplatin—esophageal cancer	9.77e-05	0.00189	CcSEcCtD
Indomethacin—Haematuria—Methotrexate—esophageal cancer	9.73e-05	0.00188	CcSEcCtD
Indomethacin—Malaise—Capecitabine—esophageal cancer	9.66e-05	0.00186	CcSEcCtD
Indomethacin—Epistaxis—Methotrexate—esophageal cancer	9.62e-05	0.00186	CcSEcCtD
Indomethacin—Vertigo—Capecitabine—esophageal cancer	9.62e-05	0.00186	CcSEcCtD
Indomethacin—Syncope—Capecitabine—esophageal cancer	9.6e-05	0.00185	CcSEcCtD
Indomethacin—Leukopenia—Capecitabine—esophageal cancer	9.59e-05	0.00185	CcSEcCtD
Indomethacin—Agranulocytosis—Methotrexate—esophageal cancer	9.52e-05	0.00184	CcSEcCtD
Indomethacin—Palpitations—Capecitabine—esophageal cancer	9.46e-05	0.00183	CcSEcCtD
Indomethacin—ABCB1—digestive system—esophageal cancer	9.42e-05	0.00257	CbGeAlD
Indomethacin—Loss of consciousness—Capecitabine—esophageal cancer	9.41e-05	0.00182	CcSEcCtD
Indomethacin—Body temperature increased—Cisplatin—esophageal cancer	9.37e-05	0.00181	CcSEcCtD
Indomethacin—Hypertension—Capecitabine—esophageal cancer	9.25e-05	0.00179	CcSEcCtD
Indomethacin—Haemoglobin—Methotrexate—esophageal cancer	9.2e-05	0.00178	CcSEcCtD
Indomethacin—Hepatitis—Methotrexate—esophageal cancer	9.16e-05	0.00177	CcSEcCtD
Indomethacin—Haemorrhage—Methotrexate—esophageal cancer	9.16e-05	0.00177	CcSEcCtD
Indomethacin—Chest pain—Capecitabine—esophageal cancer	9.12e-05	0.00176	CcSEcCtD
Indomethacin—PTGS1—lymph node—esophageal cancer	9.1e-05	0.00248	CbGeAlD
Indomethacin—Anxiety—Capecitabine—esophageal cancer	9.09e-05	0.00175	CcSEcCtD
Indomethacin—Discomfort—Capecitabine—esophageal cancer	9.01e-05	0.00174	CcSEcCtD
Indomethacin—Confusional state—Capecitabine—esophageal cancer	8.81e-05	0.0017	CcSEcCtD
Indomethacin—Oedema—Capecitabine—esophageal cancer	8.74e-05	0.00169	CcSEcCtD
Indomethacin—Hypersensitivity—Cisplatin—esophageal cancer	8.74e-05	0.00169	CcSEcCtD
Indomethacin—PTGS2—lymph node—esophageal cancer	8.7e-05	0.00237	CbGeAlD
Indomethacin—Erythema multiforme—Methotrexate—esophageal cancer	8.66e-05	0.00167	CcSEcCtD
Indomethacin—Shock—Capecitabine—esophageal cancer	8.6e-05	0.00166	CcSEcCtD
Indomethacin—Thrombocytopenia—Capecitabine—esophageal cancer	8.56e-05	0.00165	CcSEcCtD
Indomethacin—Tinnitus—Methotrexate—esophageal cancer	8.54e-05	0.00165	CcSEcCtD
Indomethacin—Tachycardia—Capecitabine—esophageal cancer	8.53e-05	0.00165	CcSEcCtD
Indomethacin—Asthenia—Cisplatin—esophageal cancer	8.51e-05	0.00164	CcSEcCtD
Indomethacin—Hyperhidrosis—Capecitabine—esophageal cancer	8.45e-05	0.00163	CcSEcCtD
Indomethacin—Anorexia—Capecitabine—esophageal cancer	8.33e-05	0.00161	CcSEcCtD
Indomethacin—Hypotension—Capecitabine—esophageal cancer	8.17e-05	0.00158	CcSEcCtD
Indomethacin—Diarrhoea—Cisplatin—esophageal cancer	8.11e-05	0.00157	CcSEcCtD
Indomethacin—Alopecia—Methotrexate—esophageal cancer	8.09e-05	0.00156	CcSEcCtD
Indomethacin—Erythema—Methotrexate—esophageal cancer	7.97e-05	0.00154	CcSEcCtD
Indomethacin—Insomnia—Capecitabine—esophageal cancer	7.91e-05	0.00153	CcSEcCtD
Indomethacin—ABCB1—lung—esophageal cancer	7.87e-05	0.00215	CbGeAlD
Indomethacin—Paraesthesia—Capecitabine—esophageal cancer	7.85e-05	0.00152	CcSEcCtD
Indomethacin—Dyspnoea—Capecitabine—esophageal cancer	7.79e-05	0.0015	CcSEcCtD
Indomethacin—Dyspepsia—Capecitabine—esophageal cancer	7.69e-05	0.00149	CcSEcCtD
Indomethacin—Decreased appetite—Capecitabine—esophageal cancer	7.6e-05	0.00147	CcSEcCtD
Indomethacin—Vomiting—Cisplatin—esophageal cancer	7.54e-05	0.00146	CcSEcCtD
Indomethacin—Fatigue—Capecitabine—esophageal cancer	7.54e-05	0.00145	CcSEcCtD
Indomethacin—Vision blurred—Methotrexate—esophageal cancer	7.51e-05	0.00145	CcSEcCtD
Indomethacin—Rash—Cisplatin—esophageal cancer	7.48e-05	0.00144	CcSEcCtD
Indomethacin—Pain—Capecitabine—esophageal cancer	7.47e-05	0.00144	CcSEcCtD
Indomethacin—Constipation—Capecitabine—esophageal cancer	7.47e-05	0.00144	CcSEcCtD
Indomethacin—Dermatitis—Cisplatin—esophageal cancer	7.47e-05	0.00144	CcSEcCtD
Indomethacin—Ill-defined disorder—Methotrexate—esophageal cancer	7.4e-05	0.00143	CcSEcCtD
Indomethacin—Anaemia—Methotrexate—esophageal cancer	7.37e-05	0.00142	CcSEcCtD
Indomethacin—Feeling abnormal—Capecitabine—esophageal cancer	7.2e-05	0.00139	CcSEcCtD
Indomethacin—Malaise—Methotrexate—esophageal cancer	7.19e-05	0.00139	CcSEcCtD
Indomethacin—Vertigo—Methotrexate—esophageal cancer	7.16e-05	0.00138	CcSEcCtD
Indomethacin—Gastrointestinal pain—Capecitabine—esophageal cancer	7.15e-05	0.00138	CcSEcCtD
Indomethacin—Leukopenia—Methotrexate—esophageal cancer	7.14e-05	0.00138	CcSEcCtD
Indomethacin—Nausea—Cisplatin—esophageal cancer	7.04e-05	0.00136	CcSEcCtD
Indomethacin—Urticaria—Capecitabine—esophageal cancer	6.94e-05	0.00134	CcSEcCtD
Indomethacin—Abdominal pain—Capecitabine—esophageal cancer	6.91e-05	0.00133	CcSEcCtD
Indomethacin—Body temperature increased—Capecitabine—esophageal cancer	6.91e-05	0.00133	CcSEcCtD
Indomethacin—Convulsion—Methotrexate—esophageal cancer	6.91e-05	0.00133	CcSEcCtD
Indomethacin—Chest pain—Methotrexate—esophageal cancer	6.79e-05	0.00131	CcSEcCtD
Indomethacin—Discomfort—Methotrexate—esophageal cancer	6.71e-05	0.00129	CcSEcCtD
Indomethacin—Confusional state—Methotrexate—esophageal cancer	6.56e-05	0.00127	CcSEcCtD
Indomethacin—Anaphylactic shock—Methotrexate—esophageal cancer	6.51e-05	0.00126	CcSEcCtD
Indomethacin—Hypersensitivity—Capecitabine—esophageal cancer	6.44e-05	0.00124	CcSEcCtD
Indomethacin—Thrombocytopenia—Methotrexate—esophageal cancer	6.37e-05	0.00123	CcSEcCtD
Indomethacin—Hyperhidrosis—Methotrexate—esophageal cancer	6.29e-05	0.00121	CcSEcCtD
Indomethacin—Asthenia—Capecitabine—esophageal cancer	6.27e-05	0.00121	CcSEcCtD
Indomethacin—Anorexia—Methotrexate—esophageal cancer	6.2e-05	0.0012	CcSEcCtD
Indomethacin—Pruritus—Capecitabine—esophageal cancer	6.18e-05	0.00119	CcSEcCtD
Indomethacin—Hypotension—Methotrexate—esophageal cancer	6.08e-05	0.00117	CcSEcCtD
Indomethacin—Diarrhoea—Capecitabine—esophageal cancer	5.98e-05	0.00115	CcSEcCtD
Indomethacin—Insomnia—Methotrexate—esophageal cancer	5.88e-05	0.00114	CcSEcCtD
Indomethacin—Paraesthesia—Methotrexate—esophageal cancer	5.84e-05	0.00113	CcSEcCtD
Indomethacin—Dyspnoea—Methotrexate—esophageal cancer	5.8e-05	0.00112	CcSEcCtD
Indomethacin—Somnolence—Methotrexate—esophageal cancer	5.78e-05	0.00112	CcSEcCtD
Indomethacin—Dizziness—Capecitabine—esophageal cancer	5.78e-05	0.00112	CcSEcCtD
Indomethacin—Dyspepsia—Methotrexate—esophageal cancer	5.73e-05	0.00111	CcSEcCtD
Indomethacin—Decreased appetite—Methotrexate—esophageal cancer	5.66e-05	0.00109	CcSEcCtD
Indomethacin—Fatigue—Methotrexate—esophageal cancer	5.61e-05	0.00108	CcSEcCtD
Indomethacin—Pain—Methotrexate—esophageal cancer	5.56e-05	0.00107	CcSEcCtD
Indomethacin—Vomiting—Capecitabine—esophageal cancer	5.56e-05	0.00107	CcSEcCtD
Indomethacin—Rash—Capecitabine—esophageal cancer	5.51e-05	0.00106	CcSEcCtD
Indomethacin—Dermatitis—Capecitabine—esophageal cancer	5.51e-05	0.00106	CcSEcCtD
Indomethacin—Headache—Capecitabine—esophageal cancer	5.48e-05	0.00106	CcSEcCtD
Indomethacin—ABCB1—lymph node—esophageal cancer	5.38e-05	0.00147	CbGeAlD
Indomethacin—Feeling abnormal—Methotrexate—esophageal cancer	5.36e-05	0.00104	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methotrexate—esophageal cancer	5.32e-05	0.00103	CcSEcCtD
Indomethacin—Nausea—Capecitabine—esophageal cancer	5.19e-05	0.001	CcSEcCtD
Indomethacin—Urticaria—Methotrexate—esophageal cancer	5.17e-05	0.000998	CcSEcCtD
Indomethacin—Abdominal pain—Methotrexate—esophageal cancer	5.14e-05	0.000993	CcSEcCtD
Indomethacin—Body temperature increased—Methotrexate—esophageal cancer	5.14e-05	0.000993	CcSEcCtD
Indomethacin—Hypersensitivity—Methotrexate—esophageal cancer	4.79e-05	0.000926	CcSEcCtD
Indomethacin—Asthenia—Methotrexate—esophageal cancer	4.67e-05	0.000901	CcSEcCtD
Indomethacin—Pruritus—Methotrexate—esophageal cancer	4.6e-05	0.000889	CcSEcCtD
Indomethacin—Diarrhoea—Methotrexate—esophageal cancer	4.45e-05	0.00086	CcSEcCtD
Indomethacin—Dizziness—Methotrexate—esophageal cancer	4.3e-05	0.000831	CcSEcCtD
Indomethacin—Vomiting—Methotrexate—esophageal cancer	4.14e-05	0.000799	CcSEcCtD
Indomethacin—Rash—Methotrexate—esophageal cancer	4.1e-05	0.000792	CcSEcCtD
Indomethacin—Dermatitis—Methotrexate—esophageal cancer	4.1e-05	0.000791	CcSEcCtD
Indomethacin—Headache—Methotrexate—esophageal cancer	4.08e-05	0.000787	CcSEcCtD
Indomethacin—Nausea—Methotrexate—esophageal cancer	3.86e-05	0.000746	CcSEcCtD
Indomethacin—CYP2C19—Metabolism—ALOX15—esophageal cancer	3.65e-06	4.29e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—KDR—esophageal cancer	3.64e-06	4.28e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—ABCB1—esophageal cancer	3.64e-06	4.27e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—NOS2—esophageal cancer	3.62e-06	4.25e-05	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—PIK3CA—esophageal cancer	3.62e-06	4.25e-05	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.61e-06	4.24e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—HMOX1—esophageal cancer	3.6e-06	4.23e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GAPDH—esophageal cancer	3.58e-06	4.2e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ALOX15—esophageal cancer	3.56e-06	4.18e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—HIF1A—esophageal cancer	3.55e-06	4.17e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CRABP1—esophageal cancer	3.55e-06	4.17e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—NOS3—esophageal cancer	3.53e-06	4.15e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.53e-06	4.15e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—TYMP—esophageal cancer	3.51e-06	4.12e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—CYP19A1—esophageal cancer	3.51e-06	4.12e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.51e-06	4.12e-05	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—TP53—esophageal cancer	3.5e-06	4.11e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—ENO1—esophageal cancer	3.48e-06	4.09e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PTGS1—esophageal cancer	3.48e-06	4.09e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GSTO1—esophageal cancer	3.48e-06	4.09e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—TPI1—esophageal cancer	3.48e-06	4.09e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—ABCB1—esophageal cancer	3.46e-06	4.06e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PSME2—esophageal cancer	3.43e-06	4.03e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PSME1—esophageal cancer	3.43e-06	4.03e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—NOTCH1—esophageal cancer	3.43e-06	4.03e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CYP26A1—esophageal cancer	3.42e-06	4.01e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GSTO1—esophageal cancer	3.4e-06	3.99e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—TPI1—esophageal cancer	3.4e-06	3.99e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GNG7—esophageal cancer	3.38e-06	3.96e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—PTGS2—esophageal cancer	3.35e-06	3.93e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—MYC—esophageal cancer	3.34e-06	3.93e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ALDOB—esophageal cancer	3.34e-06	3.92e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ALOX15—esophageal cancer	3.33e-06	3.91e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.32e-06	3.89e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—ERBB2—esophageal cancer	3.3e-06	3.88e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—EGFR—esophageal cancer	3.27e-06	3.84e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ALDOB—esophageal cancer	3.26e-06	3.83e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—CREBBP—esophageal cancer	3.25e-06	3.82e-05	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism—PIK3CA—esophageal cancer	3.25e-06	3.82e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—NOS2—esophageal cancer	3.23e-06	3.79e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GAPDH—esophageal cancer	3.21e-06	3.77e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—EP300—esophageal cancer	3.21e-06	3.77e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—HMOX1—esophageal cancer	3.2e-06	3.76e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—NOTCH1—esophageal cancer	3.2e-06	3.76e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CRABP1—esophageal cancer	3.19e-06	3.74e-05	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	3.18e-06	3.73e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GSTO1—esophageal cancer	3.18e-06	3.73e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—TPI1—esophageal cancer	3.18e-06	3.73e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ALDH2—esophageal cancer	3.16e-06	3.71e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.14e-06	3.69e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GAPDH—esophageal cancer	3.14e-06	3.68e-05	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.13e-06	3.68e-05	CbGpPWpGaD
Indomethacin—PPARA—Gene Expression—MYC—esophageal cancer	3.12e-06	3.67e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CREBBP—esophageal cancer	3.11e-06	3.65e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CRABP1—esophageal cancer	3.11e-06	3.65e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—CREBBP—esophageal cancer	3.1e-06	3.64e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—CREBBP—esophageal cancer	3.1e-06	3.64e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—TGFBR2—esophageal cancer	3.08e-06	3.61e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—ABCB1—esophageal cancer	3.07e-06	3.61e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—EGFR—esophageal cancer	3.06e-06	3.59e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.05e-06	3.59e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ALDOB—esophageal cancer	3.05e-06	3.57e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GNG7—esophageal cancer	3.03e-06	3.56e-05	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.03e-06	3.56e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—GSTT1—esophageal cancer	3.01e-06	3.53e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CYP2A6—esophageal cancer	2.97e-06	3.49e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—CYP1B1—esophageal cancer	2.96e-06	3.48e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.96e-06	3.48e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GNG7—esophageal cancer	2.96e-06	3.47e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—CREBBP—esophageal cancer	2.93e-06	3.44e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.93e-06	3.44e-05	CbGpPWpGaD
Indomethacin—CXCL8—GPCR downstream signaling—PIK3CA—esophageal cancer	2.92e-06	3.43e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CCND1—esophageal cancer	2.92e-06	3.43e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—SMAD4—esophageal cancer	2.91e-06	3.42e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—NOS3—esophageal cancer	2.91e-06	3.42e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.9e-06	3.41e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CREBBP—esophageal cancer	2.9e-06	3.41e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.85e-06	3.35e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.84e-06	3.33e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—PIK3CA—esophageal cancer	2.84e-06	3.33e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CDKN1A—esophageal cancer	2.82e-06	3.32e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ENO1—esophageal cancer	2.82e-06	3.31e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PTGS1—esophageal cancer	2.82e-06	3.31e-05	CbGpPWpGaD
Indomethacin—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.82e-06	3.31e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—NOS3—esophageal cancer	2.79e-06	3.27e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—EP300—esophageal cancer	2.79e-06	3.27e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—CYP19A1—esophageal cancer	2.79e-06	3.27e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PSME1—esophageal cancer	2.78e-06	3.26e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PSME2—esophageal cancer	2.78e-06	3.26e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—NOS3—esophageal cancer	2.78e-06	3.26e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—NOS3—esophageal cancer	2.78e-06	3.26e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ALDH2—esophageal cancer	2.77e-06	3.25e-05	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—PIK3CA—esophageal cancer	2.77e-06	3.25e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GNG7—esophageal cancer	2.76e-06	3.24e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.75e-06	3.23e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.7e-06	3.17e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—CREBBP—esophageal cancer	2.7e-06	3.17e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—EP300—esophageal cancer	2.69e-06	3.16e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.67e-06	3.13e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.66e-06	3.12e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—PIK3CA—esophageal cancer	2.65e-06	3.12e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—GSTT1—esophageal cancer	2.64e-06	3.09e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—NOS3—esophageal cancer	2.63e-06	3.08e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.61e-06	3.07e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—ERBB2—esophageal cancer	2.61e-06	3.06e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.61e-06	3.06e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—NOS3—esophageal cancer	2.6e-06	3.05e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ALDH2—esophageal cancer	2.59e-06	3.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—HMOX1—esophageal cancer	2.54e-06	2.98e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PTGS2—esophageal cancer	2.54e-06	2.98e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PTGS2—esophageal cancer	2.54e-06	2.98e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.53e-06	2.97e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ENO1—esophageal cancer	2.53e-06	2.97e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—CREBBP—esophageal cancer	2.52e-06	2.96e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—CREBBP—esophageal cancer	2.52e-06	2.96e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.49e-06	2.93e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PSME2—esophageal cancer	2.49e-06	2.93e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PSME1—esophageal cancer	2.49e-06	2.93e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ENO1—esophageal cancer	2.47e-06	2.9e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PTGS1—esophageal cancer	2.47e-06	2.9e-05	CbGpPWpGaD
Indomethacin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.47e-06	2.9e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.46e-06	2.89e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—ABCB1—esophageal cancer	2.44e-06	2.86e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.43e-06	2.86e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PSME2—esophageal cancer	2.43e-06	2.86e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PSME1—esophageal cancer	2.43e-06	2.86e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—CREBBP—esophageal cancer	2.43e-06	2.85e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—ERBB2—esophageal cancer	2.43e-06	2.85e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.43e-06	2.85e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.42e-06	2.85e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—NOS3—esophageal cancer	2.42e-06	2.84e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—PTGS2—esophageal cancer	2.4e-06	2.82e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CYP1B1—esophageal cancer	2.4e-06	2.81e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—HIF1A—esophageal cancer	2.38e-06	2.8e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—PIK3CA—esophageal cancer	2.38e-06	2.79e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—PTGS2—esophageal cancer	2.38e-06	2.79e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MYC—esophageal cancer	2.34e-06	2.75e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.32e-06	2.73e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—CREBBP—esophageal cancer	2.31e-06	2.71e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PTGS1—esophageal cancer	2.31e-06	2.71e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ENO1—esophageal cancer	2.31e-06	2.71e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CCND1—esophageal cancer	2.3e-06	2.7e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—EGFR—esophageal cancer	2.29e-06	2.69e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PSME1—esophageal cancer	2.27e-06	2.67e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PSME2—esophageal cancer	2.27e-06	2.67e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—NOS3—esophageal cancer	2.26e-06	2.65e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—NOS3—esophageal cancer	2.26e-06	2.65e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CYP19A1—esophageal cancer	2.25e-06	2.65e-05	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—MYC—esophageal cancer	2.24e-06	2.63e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CDKN1A—esophageal cancer	2.23e-06	2.62e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—EP300—esophageal cancer	2.22e-06	2.6e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PTGS2—esophageal cancer	2.21e-06	2.6e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.18e-06	2.56e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—NOS3—esophageal cancer	2.18e-06	2.55e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—NOS2—esophageal cancer	2.17e-06	2.55e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.15e-06	2.53e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—NOTCH1—esophageal cancer	2.15e-06	2.52e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—EP300—esophageal cancer	2.12e-06	2.49e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—EP300—esophageal cancer	2.11e-06	2.48e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—EP300—esophageal cancer	2.11e-06	2.48e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.1e-06	2.47e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—CDKN1A—esophageal cancer	2.08e-06	2.44e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—NOS3—esophageal cancer	2.07e-06	2.43e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PTGS2—esophageal cancer	2.06e-06	2.42e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PTGS2—esophageal cancer	2.06e-06	2.42e-05	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—PIK3CA—esophageal cancer	2.06e-06	2.42e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—HMOX1—esophageal cancer	2.06e-06	2.41e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—CREBBP—esophageal cancer	2.05e-06	2.41e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.02e-06	2.38e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.02e-06	2.37e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—EP300—esophageal cancer	2e-06	2.34e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PTGS2—esophageal cancer	1.99e-06	2.34e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—PIK3CA—esophageal cancer	1.99e-06	2.33e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.99e-06	2.33e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—EP300—esophageal cancer	1.98e-06	2.32e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.97e-06	2.32e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ABCB1—esophageal cancer	1.97e-06	2.32e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.96e-06	2.3e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CREBBP—esophageal cancer	1.95e-06	2.29e-05	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—TP53—esophageal cancer	1.92e-06	2.26e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PTGS2—esophageal cancer	1.89e-06	2.22e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MYC—esophageal cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.85e-06	2.17e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.84e-06	2.17e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.84e-06	2.17e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—NOS3—esophageal cancer	1.84e-06	2.16e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—EP300—esophageal cancer	1.84e-06	2.16e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.81e-06	2.13e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—EGFR—esophageal cancer	1.81e-06	2.12e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—HMOX1—esophageal cancer	1.8e-06	2.12e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.77e-06	2.08e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—NOS3—esophageal cancer	1.74e-06	2.05e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—MYC—esophageal cancer	1.72e-06	2.02e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—EP300—esophageal cancer	1.72e-06	2.01e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—EP300—esophageal cancer	1.72e-06	2.01e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—EGFR—esophageal cancer	1.68e-06	1.98e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.68e-06	1.98e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PTGS2—esophageal cancer	1.68e-06	1.97e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—EP300—esophageal cancer	1.65e-06	1.94e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.65e-06	1.94e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—PIK3CA—esophageal cancer	1.64e-06	1.92e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—CREBBP—esophageal cancer	1.63e-06	1.91e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—ERBB2—esophageal cancer	1.63e-06	1.91e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.62e-06	1.9e-05	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—TP53—esophageal cancer	1.59e-06	1.86e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—EP300—esophageal cancer	1.57e-06	1.85e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—PIK3CA—esophageal cancer	1.57e-06	1.84e-05	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PIK3CA—esophageal cancer	1.56e-06	1.83e-05	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PIK3CA—esophageal cancer	1.56e-06	1.83e-05	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—TP53—esophageal cancer	1.52e-06	1.78e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.49e-06	1.75e-05	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—PIK3CA—esophageal cancer	1.48e-06	1.73e-05	CbGpPWpGaD
Indomethacin—ABCC1—Disease—PIK3CA—esophageal cancer	1.46e-06	1.72e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—NOS3—esophageal cancer	1.46e-06	1.71e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—EP300—esophageal cancer	1.4e-06	1.64e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—CDKN1A—esophageal cancer	1.39e-06	1.64e-05	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	1.36e-06	1.6e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.34e-06	1.57e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—EP300—esophageal cancer	1.33e-06	1.56e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—CREBBP—esophageal cancer	1.32e-06	1.55e-05	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PIK3CA—esophageal cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.27e-06	1.49e-05	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PIK3CA—esophageal cancer	1.22e-06	1.44e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.22e-06	1.43e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.18e-06	1.39e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—NOS3—esophageal cancer	1.18e-06	1.39e-05	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	1.16e-06	1.37e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—CREBBP—esophageal cancer	1.16e-06	1.36e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—MYC—esophageal cancer	1.16e-06	1.36e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—EGFR—esophageal cancer	1.13e-06	1.33e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—EP300—esophageal cancer	1.11e-06	1.3e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PTGS2—esophageal cancer	1.08e-06	1.27e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.08e-06	1.27e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—NOS3—esophageal cancer	1.06e-06	1.24e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—NOS3—esophageal cancer	1.04e-06	1.22e-05	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PIK3CA—esophageal cancer	1.03e-06	1.21e-05	CbGpPWpGaD
Indomethacin—PTGS2—Disease—PIK3CA—esophageal cancer	9.81e-07	1.15e-05	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PTGS2—esophageal cancer	9.7e-07	1.14e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—NOS3—esophageal cancer	9.67e-07	1.14e-05	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PTGS2—esophageal cancer	9.47e-07	1.11e-05	CbGpPWpGaD
Indomethacin—ALB—Metabolism—EP300—esophageal cancer	8.99e-07	1.05e-05	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PTGS2—esophageal cancer	8.84e-07	1.04e-05	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—PIK3CA—esophageal cancer	8.22e-07	9.64e-06	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—EP300—esophageal cancer	8.07e-07	9.47e-06	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—EP300—esophageal cancer	7.87e-07	9.24e-06	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—EP300—esophageal cancer	7.36e-07	8.63e-06	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PIK3CA—esophageal cancer	6.65e-07	7.8e-06	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PIK3CA—esophageal cancer	5.97e-07	7e-06	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.82e-07	6.84e-06	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PIK3CA—esophageal cancer	5.44e-07	6.39e-06	CbGpPWpGaD
